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Abstract
Objective
Scores on the Health Assessment Questionnaire (HAQ) predict the need for support mea-
sures in patients with rheumatoid arthritis (RA). In this study we compare the performance
of the HAQ in this context with that of the more disease-specific Belgian Rheumatoid Arthri-
tis Disability Assessment (BRADA) questionnaire.
Methods
In this multicenter observational study, patients with RA and disease duration of at least one
year who consulted their rheumatologist for a routine follow-up visit filled out the HAQ, and
BRADA questionnaires. The performance of HAQ and BRADA to predict the need for sup-
port measures available to patients with RA was evaluated using Receiver Operator Char-
acteristic (ROC) curves, with the expert opinion of the rheumatologist as a reference.
Results
The study analyzed data of 301 patients with RA (70.8% females) with mean age 59.8±
12.8, disease duration 11.4±9.3 years, and DAS28 values of 2.84±1.18. HAQ scores aver-
aged 0.97±0.73 and BRADA scores were 3.92±3.49 over the last week and 3.89±3.50 over
the last 3 months. The area under the ROC curves for the BRADA scores for the support
measures investigated ranged from 0.702 to 0.862 and did not differ significantly from those
of the HAQ (range 0.725–0.860).
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Conclusion
The disease-specific BRADA questionnaire is equivalent to the HAQ in predicting the need
for support measures in patients with stable RA.
Introduction
Rheumatoid arthritis (RA) is characterized by chronic joint inflammation and can have a
major impact on human functioning and health-related quality of life [1]. RA can lead to sub-
stantial impairment of mobility, loss of productivity and disability due to pain, fatigue and
structural joint damage [2,3].
To limit the impact of the disease and safeguard patients’ quality of life, optimal care for
patients with RA encompasses a combination of medical treatment targeting RA inflammatory
pathways, complemented with support measures to address activity limitations, promote par-
ticipation and compensate extra costs and income loss due to the disease [4,5].
Fair and equitable allocation of support measures for patients with RA warrants the need
for instruments to assess the impact of the disease in a standardized way, the type and level of
activity limitations and to determine the type of support measures needed in individual
patients.
The Health Assessment Questionnaire (HAQ) is a well-validated general patient-reported
outcome instrument developed three decades ago by Fries and colleagues at Stanford Univer-
sity with proven validity and reliability in patients with RA [6–10]. In the United Kingdom, the
HAQ has been shown to predict successful application for benefits and financial support mea-
sures: 69% of patients with RA or osteoarthritis of hip or knee and a HAQ score>1.5 success-
fully applied for benefits [11–13]. In these studies, HAQ scores2 [11] or1.5 [12,13]
predicted successful application for the Disability Living Allowance (DLA) and Attendance
Allowance (AA) benefits. These are non-means tested benefits awarded to people under 65 for
the DLA, and those aged 65 and over for the AA, respectively, on the basis of their need for per-
sonal care and/or their difficulties with mobility. In these studies, RA patients selected based
on their HAQ scores were then assisted by a professional welfare worker in applying for the
DLA or AA benefits.
We previously observed that HAQ score is a good predictor of the need for support mea-
sures in adult patients with RA and a disease duration of at least one year assessed against the
expert opinion of the treating rheumatologist as a reference [14]. In this context, the HAQ per-
formed better than SF-36 scores or DAS28 [14].
However, the HAQ is a general and not a disease-specific questionnaire. We recently devel-
oped and validated a more disease-specific questionnaire to evaluate chronic activity limita-
tions in patients with RA, the Belgian Rheumatoid Arthritis Disability Assessment (BRADA)
questionnaire [15]. In addition to the domains covered by the HAQ, the BRADA questionnaire
incorporates additional elements from the International Classification of Functioning, Disabil-
ity and Health (ICF) core set for RA [16–18] and assesses the level of functioning in 6 domains
(mobility, nutrition, self-care, household tasks, awareness of danger and communication) over
the last week and the last 3 months [15]. The BRADA questionnaire therefore represents a suit-
able model to challenge the performance of the HAQ in predicting the need for support mea-
sures in patients with RA.
The performance of the BRADA to assess and predict the need for support measures in
patients with RA has not been investigated up to now. In this study, we therefore compare the
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performance of the new disease-specific questionnaire BRADA with that of the more generic
HAQ in predicting the need of support measures in patients with RA. We aim to investigate
whether patient questionnaire tools to assess functional limitations in patients with RA could
also be used to determine the need for support measures in these patients.
Patients and Methods
Ethics Statement
The BRADA study was performed in different rheumatologic centers in Belgium (UZ, Gent;
AZ Sint-Lucas, Gent; AZ Alma Sijsele; GHDC Hôpital Sint-Joseph Gilly, Charleroi; ULB
Erasme, Brussel; UCL, Brussel; AZ Sint-Lucas, Brugge; ASZ, Aalst; GHC Saint-Joseph, Luik;
UZ Gasthuisberg, Leuven; CHU Sart Tilman de Liège, Liège; Clinique Saint-Pierre, Ottignies).
The ethical committee of the Ghent University Hospital acted as central EC for this study (dos-
sier 2010/094) and approved the study on behalf of all participating centers (unique study Bel-
gian study id covering all centers: B67020108165, date of approval: 29-Jul-2010). Approval of
this EC to start the study explicitly means that all other EC of the peripheral centers have given
written permission to start the study also in their center. Written informed consent was
obtained from all patients before inclusion in the study.
Study Design
The setup of this multicenter observational study was extensively described in a previous study
[14]. Briefly, the study included patients of at least 18 years of age who fulfilled the American
College of Rheumatology diagnostic criteria for RA [19] and had a disease duration of at least
one year. No specific exclusion criteria were defined. To ensure an unbiased, representative
population of patients with relatively stable RA, only the first patients in every consultation
block who consulted their rheumatologist for routine outpatient evaluation were eligible for
inclusion in the study. Patients who gave their written informed consent were included in the
study and proceeded with the study data collection in the same visit.
Data collection
Data collected comprised patient demographics, disease history, current treatment, DAS28
[20], short HAQ [7] and BRADA [15] questionnaires. The supplementary S1 File contains the
study data and a complete list of study variables.
DAS28 is a well validated composite disease activity index for RA, calculated with the num-
ber of tender and swollen joints in a standard 28 joint count, a laboratory parameter (ESR or
CRP) and optionally the patient global health VAS score as input variables. DAS28 values
below 3.2 indicate low disease activity, those above 5.1 high disease activity. [21,22].
The HAQ has become a widely used patient reported outcomes tool to asses functional status
in the three decades since its inception by Fries and colleagues at Stanford University, both in the
context of clinical trials and in daily clinical practice [23,24]. It has been translated in many lan-
guages and has proven validity and reliability in patients with RA [9,10]. Higher scores on the
HAQ indicate increasing levels of disability: scores 0 to 1 are considered to reflect mild to moder-
ate difficulty, 1 to 2 moderate to severe disability and 2 to 3 severe to very severe disability [7].
The BRADA questionnaire is a patient reported questionnaire covering all domains of the
HAQ and additionally incorporating a number of elements from the ICF core set for RA.
BRADA assesses functioning in 6 domains (mobility, nutrition, self-care, household tasks,
awareness of danger and communication). For each domain, the patient scores his/her ability
to perform 6 activities during the last week as well as in the last three months as: without
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difficulty (score 0), with some difficulty (score 1), very difficult (score 2), impossible (score 3).
The BRADA questionnaire yields two total scores ranging from 0 to 18 for functional status over
the last week and the last three months, with higher scores indicating higher functional limita-
tions. BRADA scores show good test-retest reliability and correlate excellently with other vali-
dated questionnaires (HAQ, SF-36) and with measures of disease activity (VAS, DAS28) [15].
The treating rheumatologists scored the need for each of 9 different supporting measures
(Table 1) available for chronically ill patients in the Belgian social security system on a four
item categorical scale as: certainly needed, probably needed, probably not needed or certainly
not needed. HAQ and BRADA questionnaires were filled out independently by the patient.
The rheumatologists were unaware of the patient’s questionnaire scores, which were only cal-
culated during data analysis.
Data analysis and statistics
BRADA scores assessing functioning over the last week and the last three months were com-
puted by averaging the six summed domain scores (mobility, nutrition, self-care, household
tasks, awareness of danger and communication) resulting in two separate overall scores (cover-
ing the last week and the last three months), both with a maximum value of eighteen, with
higher scores representing increasing activity limitations [15]. Certain support measures relate
specifically to the activities of the mobility domain (parking card, vehicle tax waiver, free public
transportation for attendant) or the communication domain (social telephone rate) of the
BRADA questionnaire. Therefore, BRADA scores were additionally computed by calculating a
weighted average of the summed domain scores with double weight factors for the mobility
and communication domains when calculating the overall BRADA scores.
Patients were excluded from analysis when HAQ or BRADA scores could not be calculated
or the rheumatologist’s recommendation on the need for support measures was missing.
Data are presented as mean±standard deviation for normally distributed variables, as
median (range) for variables not following a normal distribution or as percentages. Statistical
analysis was performed with SPSS version 20 software (IBM Corporation, Armonk, New York,
USA). The Kolmogorov-Smirnov test was used to assess the normal distribution of variables.
The performance of the HAQ and BRADA questionnaires as tests to predict the need for
support measures by patients with RA was evaluated by comparing the area under the curve
Table 1. Support measures for chronically ill patients investigated in this study.
Support measure Type Description
Integration allowance Financial beneﬁt (<65
years)
To compensate extra costs due to diminished autonomy and to enhance social participation of
person with special needs.
Allowance for help to the
aged
Financial beneﬁt (>65
years)
For seniors with chronic health disorders confronted with supplementary costs due to loss of
autonomy, in order to enhance their social participation.
Tax reduction Tax beneﬁt Income tax exemption for families with one or more disabled persons.
Parking card Promotion of mobility For persons with mobility restrictions. Allows parking in parking places reserved for disabled
persons and parking without time limit in areas of time restricted parking.
Vehicle tax waiver Tax beneﬁt Exemption of car tax for disabled persons.
Free public transportation for
attendant
Promotion of mobility Free public transportation access for companions of people with mobility restrictions who can’t
travel alone.
Social telephone rate Cost reduction Reduced telephone connection rate, subscription fee and call charges for people with functional
limitations.
Social rate utility services Cost reduction Exemption of regular allowance and free delivery of a ﬁxed amount of gas and electricity for
disabled persons.
Allowance for chronic illness Financial beneﬁt (<65
years)
Premium for persons with a chronic disease confronted with high medical costs.
doi:10.1371/journal.pone.0146688.t001
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(AUC) of Receiver Operator Characteristics (ROC) curves [25], with the recommendation of
the treating rheumatologist for all nine support measures evaluated as the reference. Scores
‘certainly needed’ and ‘probably needed’ were considered a positive recommendation for a par-
ticular support measure. The AUCs of the ROC curves for HAQ and BRADA scores were com-
pared using ANOVA.
A p-value<0.05 was considered statistically significant.
Results
Population characteristics
Informed consent was obtained from 316 patients, but the study population analyzed con-
tained 301 patients: fifteen patients were excluded from analysis because (more than one rea-
son possible): HAQ (n = 4) or BRADA (n = 5) scores could not be calculated or the
rheumatologist’s recommendation on the need for support measures was missing (n = 8).
Patients in this study were 59.8±12.8 years old and had an average RA disease duration
of more than ten years (Table 2).
The study recruited patients who consulted their rheumatologist for a routine outpatient
check-up and thus consisted of patients with relatively stable disease: treatment was changed
during the study visit in only 14.8% of patients and the mean DAS28 value of 2.84±1.18 indi-
cated low disease activity.
Current RA treatment included DMARDs in most of patients (86.4%, 50.5% treated exclu-
sively with DMARDS); biologicals were given to nearly half of the patients (47.2%).
BRADA and HAQ scores
BRADA scores evaluating functioning over the last week averaged 3.92±3.49, whereas the
BRADA scores covering the patients’ assessment of their functioning over the last 3 months
were 4.12±3.51 (Table 3).
Table 2. Population characteristics.
Population characteristics Overall
Nr of patients 301
Age (y) 59.8 ± 12.8
Gender ratio (% female) 70.8
RA characteristics
Disease duration (y) 11.4±9.3
RF (% positive) 73.5
Anti-CCP (% positive) 60.1
Erosions (% positive) 67.3
DAS 28 2.84 ± 1.18
Treatment (% of patients)
DMARDs 86.4
DMARDs–no biologicals 50.5
Biologicals 47.2
Corticosteroids 44.2
NSAIDs 42.9
Data are expressed as mean±standard deviation or as percentages.
Abbreviations: anti-CCP: anti-cyclic citrullinated peptide antibody, DAS28: disease activity score using 28
joint counts, DMARDs: Disease-modifying anti-rheumatic drugs, NSAIDs: non-steroidal anti-inﬂammatory
drugs, RF: rheumatoid factor
doi:10.1371/journal.pone.0146688.t002
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BRADA double weighted scores are the results of an alternative computing of the BRADA
score where the overall one week and three month BRADA scores are calculated as a weighted
average of the summed domain scores, with double weight given to the mobility and communi-
cations domains. Data are expressed as mean±standard deviation or as percentages.
Additionally, BRADA total scores were computed with an alternative method as a weighted
average of the domain scores giving double weight to the mobility and communications
domains because four out of nine support measures investigated specifically concern activities
related to the mobility or communications domain of the BRADA questionnaire. BRADA
scores with double weighting for the mobility and communication domains were 3.89±3.50 for
the last week and 4.09±3.52 for the last 3 months, respectively.
HAQ scores were 0.97±0.73 and 40.2% of patients (n = 121) had a HAQ score>1 (Table 3).
Comparison of BRADA and HAQ as predictors for the need of support
measures
ROC curves for every support measure investigated are presented in Fig 1. The AUCs of
these ROC curves are summarized in Table 4. The ROC curve AUCs were consistently>0.7
for all support measures investigated (range 0.702–0.862 for BRADA and 0.725–0.860 for
HAQ) and did not differ significantly for BRADA and HAQ (ANOVA, p = 0.787).
ROC curves comparing BRADA and HAQ in predicting the need for support measures
were also constructed using the BRADA scores calculated as weighted average with double
weighting for the mobility and communications domains (data not shown). This alternative
computation of the BRADA scores yielded results comparable to those of the standard
BRADA computation: AUCs of the ROC curves for both computation methods did not differ
significantly. Neither did the AUCs for BRADA scores with double weighting of the mobility
and communications domains differ significantly from those of the HAQ (Table 4).
Discussion
Patients with RA are confronted with activity limitations, participation issues and additional
costs [4,26–28]. Optimal care for these patients therefore needs to encompass both medical
treatment and support measures to compensate the difficulties they experience in performing
daily activities and participating in society.
In this study we compared the performance of the disease-specific BRADA questionnaire
with the well-known and widely used generic HAQ for predicting the need for support mea-
sures in patients with stable, longstanding RA.
The BRADA questionnaire was found to be a suitable tool for predicting the need for sup-
port measures in patients with RA as assessed by their rheumatologist, as ROC curve AUCs
Table 3. BRADA and HAQ scores.
BRADA 1 week 3.92±3.49
3 months 4.12±3.51
BRADA double weighted 1 week 3.89±3.50
3 months 4.09±3.52
HAQ 0.97±0.73
% HAQ >1 40.2
Abbreviations: BRADA: Belgian Rheumatoid Arthritis Disability Assessment, HAQ: Health Assessment
Questionnaire
doi:10.1371/journal.pone.0146688.t003
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Fig 1. ROC curves comparing BRADA and HAQ as predictors for the need of support measures in patients with RA.Rheumatologists evaluated their
patients’ need for each of the nine support measures currently available in Belgium. Receiver Operator Characteristics Curves (ROC) comparing the
performance of the BRADA questionnaire scores with the HAQ in predicting the need for support measures, taking the positive recommendation of the
rheumatologist as a reference. These ROCs show that BRADA and HAQ perform comparably well for all support measures evaluated.
doi:10.1371/journal.pone.0146688.g001
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were consistently above 0.7 for all support measures investigated. Somewhat surprisingly, per-
formance of the BRADA questionnaire in this context was equivalent to but not better than
that of the HAQ.
The BRADA questionnaire encompasses all eight domains of the HAQ and additionally
contains a number of elements from the ICF core set for RA, that were added to make the ques-
tionnaire disease-specific. The additional ICF elements added mainly involve mobility (such as
riding a bicycle, driving a car, moving around the house), self-reliance (e.g. get up after a fall,
get medication out of the package and take it) and communication (e.g. use a computer, use a
telephone) or participation items such as the ability to go to public buildings or participate in a
one-day outing.
Possibly, the incorporated ICF elements did not significantly change the performance of the
BRADA questionnaire to predict the need of certain support measures in this study over that
of the HAQ since the study population comprised stable patients with relatively low disease
activity (DAS28 of 2.84 ± 1.18). It is as yet unclear whether the results of this study can be
extrapolated to a population of RA patients with higher disease activity.
The fact that the BRADA is designed to estimate functioning over the last week as well as
over the last three months targets the scope of this questionnaire toward the evaluation of sta-
ble long-term activity limitations and disability in patients with RA. The low disease activity
and relatively low HAQ scores in the study population indicate that most patients with RA,
even those with long-standing disease, function well under treatment.
The current study does not include data on actual support applications or allocations. If
available, such data could have been used as reference in an additional ROC curve analysis to
Table 4. Area under the curve of Receiver operator curves comparing the performance of BRADA and HAQ scores in predicting the need for sup-
port measures in patients with RA.
BRADA BRADA—Double Weighted HAQ
1 week 3 months 1 week 3 months
Integration allowance (<65 y) 0.806 0.771 0.805 0.773 0.801
(0.740–0.871) (0.701–0.841) (0.739–0.871) (0.703–0.843) (0.735–0.876)
Allowance for help to the aged (>65 y) 0.829 0.805 0.836 0.809 0.815
(0.749–0.909) (0.720–0.891) (0.758–0.914) (0.724–0.894) (0.732–0.899)
Tax reduction 0.777 0.755 0.776 0.754 0.783
(0.723–0.831) (0.699–0.811) (0.722–0.830) (0.698–0.810) (0.730–0.836)
Parking card 0.862 0.840 0.866 0.845 0.860
(0.818–0.905) (0.792–0.888) (0.814–0.909) (0.798–0.891) (0.816–0.903)
Vehicle tax waiver 0.790 0.779 0.795 0.787 0.793
(0.738–0.842) (0.726–0.833) (0.743–0.846) (0.734–0.839) (0.741–0.844)
Free public transportation for attendant 0.734 0.733 0.741 0.738 0.727
(0.669–0.798) (0.667–0.799) (0.677–0.804) (0.673–0.804) (0.662–0.791)
Social telephone rate 0.776 0.754 0.773 0.751 0.785
(0.723–0.830) (0.698–0.810) (0.720–0.827) (0.695–0.807) (0.732–0.837)
Social rate utility services 0.776 0.76 0.779 0.761 0.769
(0.723–0.830) (0.705–0.816) (0.726–0.833) (0.705–0.816) (0.714–0.823)
Allowance for chronic illness 0.706 0.702 0.707 0.701 0.725
(0.645–0.767) (0.639–0.765) (0.645–0.768) (0.639–0.763) (0.664–0.786)
AUCs of ROC curves (95% conﬁdence interval) for the BRADA and HAQ questionnaires were comparable (ANOVA, p = 0.787). The recommendation of
the treating rheumatologist for each support measure analyzed was used as a reference.
doi:10.1371/journal.pone.0146688.t004
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investigate the performance of the BRADA and HAQ questionnaires in predicting (successful)
application for support measures. However, such analysis would compare these questionnaires
to existing application and allocation procedures, which may not always be adequately tailored
to the needs of patients with rheumatoid arthritis.
As patient reported outcomes measures, both HAQ and BRADA questionnaires inherently
carry an element of subjectivity. However, patient questionnaire scores for physical function
were shown to be superior to laboratory tests and radiographs in predicting severe outcomes in
RA such as mortality and work disability [29].
Although further research is needed in order to investigate optimal cut-off values in popula-
tions with different disease severity, and to determine which level of questionnaire scores opti-
mally predicts the need for specific support measures, the current study demonstrates that
patient questionnaires HAQ and BRADA are reliable, standardized tools to measure activity
limitation in patients with RA, both as clinical follow up instruments and as tools to assess the
need of support measures.
The main impact and relevance this study and research on the use of patient questionnaires
to predict the need of additional support measures in patients with RA may have on clinical
practice in rheumatology, is to raise rheumatologists’ awareness. Awareness that first and fore-
most patients with RA are in need of support–in additon to optimal medical treatment and
often even when remission has been achieved—to alleviate the consequences of the disease on
their quality of life. Awareness that they as rheumatologists are in a good position to inform
their patients and direct them to additional support measures, using the same instruments
(questionnaires such as BRADA and HAQ) they use to assess activity limitations of their
patients.
Further research is needed to confirm our findings in populations in populations with RA
with different disease activity and disability levels, and establish suitable threshold scores for
different types of support measures; Rasch analysis [30] of the BRADA questionnaire will be
needed to identify the optimal combination of items to investigate functioning in populations
with different levels of functional impairment or disability.
This type of research ultimately may have an impact on the policies government support
agencies use to allocate support measures to patients and to distribute the funds for these sup-
port measures equitably and according to objective criteria to those most in need of these sup-
port measures.
In summary, disease-specific BRADA questionnaire is able to adequately predict the need
for support measures in patients with stable RA and performs equally well but not better than
the HAQ in this context.
Supporting Information
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